Sugi Predict

Sugi Predict / Compounds / SCHEMBL16637180

SCHEMBL16637180

SCHEMBL16637180

CN(C)C(=O)C1CN(C(=O)OC(C)(C)C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 3/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SETD7 Q8WTS6 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ NR1H2 P55055 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP7 P09237 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28444814 0.92 HSD17B10 (0.43) USP30HSD17B10USP2SMN1; SMN2SETD7
SCHEMBL34473207 0.92 HSD17B10 (0.43) USP30HSD17B10USP2SMN1; SMN2SETD7
SCHEMBL15645271 0.87 NR1H2 (0.41) USP30HSD17B10USP2SMN1; SMN2SETD7
SCHEMBL20584042 0.87 NR1H2 (0.41) USP30HSD17B10USP2SMN1; SMN2SETD7
SCHEMBL27044060 0.87 NR1H2 (0.41) USP30HSD17B10USP2SMN1; SMN2SETD7
SCHEMBL22227 0.83 HSD17B10 (0.51) HSD17B10USP2SMN1; SMN2SETD7NR1H2
SCHEMBL4662077 0.83 HSD17B10 (0.45) HSD17B10USP2SMN1; SMN2SETD7NR1H2
SCHEMBL20583847 0.83 HSD17B10 (0.45) HSD17B10USP2SMN1; SMN2SETD7NR1H2
SCHEMBL2364954 0.83 HSD17B10 (0.51) HSD17B10USP2SMN1; SMN2SETD7NR1H2
SCHEMBL18027 0.83 HSD17B10 (0.51) HSD17B10USP2SMN1; SMN2SETD7NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS USP30 746/4885HSD17B10 4418/4885USP2 1476/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS USP30 2694/4885HSD17B10 4831/4885USP2 1546/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2694/4885HSD17B10 4831/4885USP2 1546/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS USP30 2330/4885HSD17B10 4752/4885USP2 1915/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS USP30 2670/4885HSD17B10 3657/4885USP2 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.